Exclusive Online Content
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
Catalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen Injectors
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it…
Major Players in Type 2 Diabetes Shifting Focus to Pricing to Maintain Market Share
The highly mature type 2 diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will see pharmaceutical companies prioritizing competitive…
